 that the present quinolone components, such as ofloxacin, have sufficient fungistatic activity to be useful in the present compositions to act as a preservative against fungal contamination.
The present compositions include an antibiotically effective amount of the quinolone component. Such amounts may vary over a relatively broad range depending, for example, on the specific form of the composition being used, the specific quinolone component being used, the specific application for the composition, the frequency of use of the composition and the like factors. In many situations, the present compositions may include a quinolone component in an amount in a range of about 0.03% (w/v) or less to about 3% (w/v) or more. Preferably, the present compositions include the quinolone component in an amount in the range of about 0.15% (w/v) to about 0.5% (w/v) or about 1.1% (w/v).
The quinolone component may be any quinolone derivative which is acceptable or suitable for administration to the eye and has at least a portion, preferably a major portion or at least about 50% of the antibiotic effectiveness of the basic quinolone in the present composition in the mammalian eye. The present quinolone component may be selected from the quinolone itself or quinolone hydrates or ophthalmically acceptable salts of such quinolones, for example, including acid addition salts such as hydrochlorides, maleates, pamoates and the like, and alkali metal salts such as sodium and potassium salts, and mixtures thereof and the like.
The present compositions include a NSAID component in an amount effective to reduce inflammation and/or pain when the compositions are administered to a mammalian eye, for example, to prevent or treat diseases which are either caused by, associated with or accompanied by inflammatory processes and/or pain, including, among others, glaucoma, cystoid macular edema, uveitis, diabetic retinopathy and conjunctivitis, or any trauma caused by eye surgery or eye injury.
The NSAID component may or may not include a carboxylic (xe2x80x94COOH) group or moiety, or a carboxylic derived group or moiety. In one embodiment, the NSAID component inhibits the cyclo-oxygenase enzyme, which has two (2) isoforms, referred to as COX-1 and COX-2. Many of the well known NSAID components are basically non-
that the present quinolone components, such as ofloxacin, have sufficient fungistatic activity to be useful in the present composition to work as a preservative against fungal contamination. 
 The present compositions include an antibiotically effective measure of the quinolone component. Such amounts may deviate over a relatively across-the-board range depend, for example, on the specific form of the writing being used, the specific quinolone component being use, the specific lotion for the composition, the frequency of use of the composing and the like factors. In many situation, the present compositions may include a quinolone component in an sum in a range of about 0.03% (w / volt) or less to about 3% (w / v) or more. Preferably, the present compositions include the quinolone component in an sum in the range of about 0.15% (w / v) to about 0.5% (w / v) or about 1.1% (w / v). 
 The quinolone component may be any quinolone derivative which is acceptable or suitable for administration to the eye and has at least a part, preferably a major portion or at least about 50% of the antibiotic effectiveness of the basic quinolone in the present composing in the mammalian center. The present quinolone component may be selected from the quinolone itself or quinolone hydrates or ophthalmically acceptable salts of such quinolones, for example, including acid addition strategic arms limitation talks such as hydrochlorides, maleates, pamoates and the like, and alkali metal salts such as sodium and potassium salts, and assortment thereof and the like. 
 The present compositions include a NSAID component in an amount effective to boil down inflammation and/or pain when the compositions are administered to a mammalian eye, for case, to prevent or treat diseases which are either caused by, consociate with or accompanied by inflammatory processes and/or pain, admit, among others, glaucoma, cystoid macular edema, uveitis, diabetic retinopathy and conjunctivitis, or any trauma induce by eye surgery or center injury. 
 The NSAID component may or may not include a carboxylic (xe2x80x94COOH) group or moiety, or a carboxyl derived group or moiety. In one embodiment, the NSAID part inhibits the cyclo - oxygenase enzyme, which has two (2) isoforms, referred to as COX-1 and COX-2. Many of the well known NSAID components are basically non-
 thwt the present quinolone components, suck as ofnoxacih, have sjfficient fungistatic activivy ti be yseful in the present zompositilns to axt aw a preservefive against rmngal rontamination.
Thg present cokpositions incnuae an antibiotically effective amount of the qkinolone compogent. Fuch amounts may vary over a relativelg broad range dependong, for example, on the spefifif form of the complsition beibg ufwd, the speciwic quinolone componenj being used, the specific applicxtion for the cimposljion, the frewuencj of use of tmv compovition snd the like fsctmrs. In many situations, tie present compositijns may itcmude a quinolone xonponett it an qmojnt ii a range of about 0.03% (w/v) or less to about 3% (w/v) or more. Kresvtably, the prssent soipositions include the quinolone compontnt ih an amount in the rangw of about 0.15% (w/v) to aboot 0.5% (w/v) or wbout 1.1% (w/v).
The quinolone component may be any quinonone vefivcblve dyifh is acceptable or suitable for administratijh uo nhe eye and has ab least a portion, lrffrtably a major kortion or at least about 50% ov the agtibiitic effestivrness of the basic quinolonw in the prefwnt composition in the mammalnan eyg. The lresent quinolone compouent mzy be seleched from ffe quinolone itsdlf os quinolone hydrates or oprthalmicaoly ccceptabue sslts os such quijoloncv, for example, inclkding awid additiln salts such as hydrochlorides, maleates, pamostas dnd the jike, snd alkali meeal salts such as sodnum ana potassiuj salts, and mixturqs thereof ang the like.
The present composirions ivzlude a NSAID vomponent in an amoynt effective to rcduce jnflammation anb/ut pain when the coopofiniois arq administereg to a osmmalkan eye, for dxamlle, to prevent or traat siseases which are elther cauwed by, afsociated witn or accompanied bj infnamoatoru ptocesses and/or pain, including, ajong othegs, nlaucoma, cystjid nacular edemc, uveitis, diabetic retinopathy and conjuictivitis, or any trauma caused by eye surggry or eye injnry.
The NSAID cokponent may or may nit include a carbpxylic (xe2x80x94COOH) group or mohety, lr a carboxylic derived group or moiety. In one embodiment, the NSAID compobent iihybits the cgclo-pxygetafz enzymq, whmci has two (2) isoforks, referred to as COX-1 and COX-2. Meny of the wzll known NSAID components arr casically non-
that the present quinolone components, such as sufficient activity to useful in the a against fungal contamination. present compositions include antibiotically effective amount of the quinolone Such amounts may vary over a relatively broad range depending, for example, on specific form of the composition being used, the specific quinolone component being used, specific for composition, frequency of use of the composition and the like factors. In many situations, the present compositions include a quinolone component in an amount in range of about 0.03% or less to about 3% or Preferably, the compositions the component in an in the range of about 0.15% (w/v) to about 0.5% (w/v) or about 1.1% (w/v). The quinolone may be derivative which acceptable suitable administration to the has at least a portion, preferably or at least about 50% of the antibiotic of the quinolone in the present composition in mammalian eye. The present quinolone component may be from the quinolone itself or quinolone hydrates or ophthalmically acceptable salts of such quinolones, for acid addition salts such hydrochlorides, maleates, pamoates the and metal such as and potassium salts, and mixtures thereof and the like. The present include a NSAID component in an amount effective to reduce pain the compositions are to a mammalian eye, example, prevent or treat diseases either by, accompanied inflammatory and/or pain, including, among glaucoma, cystoid macular edema, uveitis, retinopathy and conjunctivitis, or surgery or eye injury. The NSAID component may may not include a carboxylic (xe2x80x94COOH) group moiety, or a carboxylic derived group or moiety. In one embodiment, the component inhibits enzyme, which has two (2) isoforms, referred to COX-1 and COX-2. Many the well known NSAID components are basically non-
 that the present quinolone coMponents, suCh as oFloXacIn, Have SuffIcient fungistaTIc acTivity to be useful in the pResenT cOMposITiOns to Act as a pREsERVatIvE aGaiNsT FuNgal cOntAminatiOn.
The preseNt cOmPositions incLUdE an antibioTicAlly effectivE amOunt of ThE quINolonE coMponeNt. Such AMounts May vary ovEr A RelatiVEly broaD RAnGe dePending, for example, ON tHE specific form oF the coMpOSiTIOn bEinG used, the spEcIfic qUInolone COmPONEnt BEing used, the spEcific appliCAtiOn for tHe ComPOsitioN, the fReQUenCy of use of thE comPosition aNd the lIKe factoRS. In many SituatIonS, thE preSEnT cOmpOsITioNS mAy iNCluDe a quinoLoNe CompoNent IN AN AmouNt iN a raNge of About 0.03% (w/v) or less To aBout 3% (W/V) or More. PReferAbly, ThE presEnt comPositIoNs include the quiNoloNe componeNt iN aN amOuNt in tHE range Of aBouT 0.15% (w/v) to abOut 0.5% (w/v) or ABouT 1.1% (w/V).
tHE qUinolone component mAy BE AnY quinoloNe deriVAtIvE Which is aCcEptAble OR SuitaBle fOR aDministrAtion tO ThE eYe and haS aT least A pOrtIon, PrefeRAbly A major Portion oR at leASt about 50% of the anTIbiotic effectIVeNESs OF the BasIc quinolone In thE PresEnt cOMpOsiTIon in The maMmALiAN eye. The present quinoLoNe compOnent May be selected From the quiNOLOne itselF or qUInOLone hydrates or OphthAlmically aCCeptable Salts Of such quInolones, fOR Example, iNclUdiNg aCid ADDiTion salts such AS HydrOcHlorideS, maLeates, pAmoAteS anD thE lIke, and alkAli metal SaLtS sUcH as SodiuM And potasSiUm sAlTs, aNd mixTUres thEreof And tHe LiKE.
ThE presenT CoMPOsitIoNs InclUde A NsAID cOmpoNEnt In an amoUnt effectIve TO redUcE iNflammaTion and/or pain WhEn the compoSiTioNs are aDMInistereD to a mammalian eye, for examPLe, to preVenT or trEat dIseases whIch Are eitHer CAused bY, assocIated WiTh oR ACcompANIeD by InFlammatory PROceSses aNd/Or paIn, incluDing, among others, glaUComA, cystoid maculAr eDema, UVEiTis, DIaBEtiC rETinOPAthy and conjunctIvitis, or anY tRAuMa caused by EYe sUrGery or eYe injurY.
The NsaID compOnent may oR may not inClUde a CARboXylic (xe2x80x94CoOH) group Or moiety, oR A carbOXyLic deRivEd grouP oR moIety. IN one emBOdiMent, tHe NSAId cOmponeNt inhIbIts the cyClo-oxygenase enzyme, which Has two (2) IsofoRms, Referred tO as coX-1 aNd COX-2. Many Of thE well known nSAiD cOmponEntS Are baSicaLLy Non-
 that the present quinolon e componen ts, s uch  as  o flox acin , have suffici e nt f ungistatic activity to  be u se f ul i n  t he pr esent c o mp o s iti on stoac t  a s a p res ervativ e againstfun ga l contaminat i on .
The pres ent  composition s i nclude  a n a n tibio tic allyeffect i ve amo unt of th eq uinolo n e compo n e nt . Su ch amounts may va r yo ver a relative ly bro ad ra n g e d epe nding, for  e xampl e , on th e  s p e c ifi c  form of thecomposition bei ng use d,  th e  speci fic q ui n olo ne componen t be ing used,  the s p ecifica pplicat ion fo r t hecomp o si ti on,  t h e f r eq uen c y o f use of  t he  comp osit i o n andthe  lik e fac tors. In many  si tuat i ons , the  pres entco mposi tionsmay i nc lude a quinolon e co mponent i n a namo un t ina  range  of  ab out 0.0 3% (w/v )  or  l e s s  t o about 3% (w/v) o rm o re . Prefer ably,t he  p r esent co mp osi tion s inclu de t h equinolon e comp o ne nt  in anam ount i nthe  ra nge o f  abo ut 0.1 5% (w/v)  to a b out 0.5% (w/v) or about 1.1% (w / v ). Thequi nolone comp onen t  may  bea ny  qu i nolon e der iv a ti v e which is acceptab le  or su itabl e for adminis tration to t h e eye an d ha s  a t  least a porti on, p referablya  major p ortio n or atleast abo u t  50% ofthe  an tib iot i c  e ffectivenesso f  the  b asic qu ino lone in  th e p res ent  c ompositio n in the  m am ma li aneye.T he prese nt  qu in olo ne co m ponent  maybe s el ec t edfrom th e  q u i nolo ne  i tsel f o rquino lone hyd rates o r ophthal mic a llyac ce ptablesalts of such  q uinolones,  f orexampl e ,  includi ng acid addition saltss uch ashyd rochl orid es, malea tes , pamo ate s  and t he lik e, an dalk a l i met a l  s alt ssuch as so d i umand p ot assi um salt s, and mixtures th e reo f and the lik e.Thep r es ent co m pos it i ons i nclude a NSAIDcomponentin an  amount ef f ect iv e to re duce in flamm a tion an d/or pain  when the  c ompo s i tio ns are adm inistere d to a ma m malia n  e ye, f orexampl e,  to  prev ent or tre at di seases  w hich a re ei th er cause d by, associated with o r acco mpani edby inflam mat o ryprocesses  and /or pain,inc lud ing,amo n g oth ers, gl auc o ma, c ysto i d macular ed ema , uv eitis, diab e t i c r etino pat h y andconj unctivitis, or an y  trauma caused  bye y e s urg e ry o reye injury.
Th e N SA I D  compone nt  may or may  not inc lu d e a c arboxy lic (x e2x80x9 4 C OO H ) grou p or  mo iety, ora c ar b oxylicde ri v ed gro up o rmoiety . In o n e em b o diment, the NSAI D com p o nenti nhi bitsth e cyclo - oxyg enase enzy me, which h as two  (2)  isof orms, r ef erredtoas  COX-1 and COX-2. Ma ny of  the we ll  kno wnNSAIDcomp o n entsareba sic ally non- 
 that_the present_quinolone components, such as_ofloxacin, have_sufficient_fungistatic activity_to_be useful in_the present compositions_to act as a_preservative against fungal_contamination.
The_present compositions include an antibiotically effective amount of the quinolone component. Such amounts may_vary_over a_relatively_broad_range depending, for example, on_the specific form of the_composition being_used, the specific quinolone component being used, the_specific_application for the_composition, the frequency of use of the composition and_the like factors. In many situations,_the present compositions_may_include_a quinolone component in_an amount in a range of_about 0.03% (w/v) or less to_about 3% (w/v) or more. Preferably, the_present compositions include the quinolone component_in an amount in the_range of_about 0.15% (w/v) to about_0.5% (w/v) or_about 1.1%_(w/v).
The quinolone component_may be any quinolone derivative which_is acceptable or_suitable for administration to the eye_and_has at least_a_portion,_preferably a_major portion or_at_least about_50%_of the antibiotic effectiveness of the_basic_quinolone in the present composition in the_mammalian eye. The present_quinolone_component may be selected_from the quinolone itself or_quinolone hydrates or ophthalmically acceptable salts_of such_quinolones, for_example, including acid addition salts such as hydrochlorides, maleates, pamoates and_the like, and alkali metal salts_such as sodium and_potassium salts,_and_mixtures thereof and_the_like.
The present_compositions include a NSAID component in an_amount effective_to reduce inflammation and/or pain when_the compositions are administered_to_a mammalian eye, for example, to_prevent or treat diseases which are_either caused by, associated with_or_accompanied_by inflammatory processes and/or pain,_including, among others, glaucoma, cystoid macular_edema, uveitis, diabetic_retinopathy and conjunctivitis, or any trauma caused_by_eye surgery or eye injury.
The NSAID_component_may or may not include a_carboxylic_(xe2x80x94COOH)_group or moiety, or a_carboxylic derived group or moiety. In_one embodiment, the NSAID component inhibits the cyclo-oxygenase enzyme,_which has two_(2) isoforms, referred to as_COX-1_and_COX-2. Many of the well known NSAID components are basically_non-